

Title (en)

METHODS FOR TREATING CELL PROLIFERATIVE DISORDERS INCLUDING CANCER

Title (de)

METHODEN ZUR BEHANDLUNG VON ZELLPROLIFERATIVEN KRANKHEITEN EINSCHLIESSLICH KREBS

Title (fr)

PROCEDES POUR TRAITER DES TROUBLES DE PROLIFERATION CELLULAIRE COMPRENANT LE CANCER

Publication

**EP 1214067 A1 20020619 (EN)**

Application

**EP 99946993 A 19990920**

Priority

- US 9921711 W 19990920
- US 39295399 A 19990909

Abstract (en)

[origin: WO0117524A1] A method of treating a cell proliferative disorder including types of cancer, causes inhibition of blood supply to the cancerous region, eg., a tumor, by administering an admixture of a predetermined quantity of a polyunsaturated fatty acid in the form of a solution of at least one polyunsaturated fatty acid together with optionally a predetermined anticancer drug, a cytokine and an oily lymphographic agent. In a preferred form, the admixture is injected intra-arterially through a catheter into an artery which provides the major blood supply to the tumor, the artery being proximate to the tumor. The solution of the polyunsaturated fatty acid may comprise an essential fatty acid(s) metabolite in salt form, eg., a lithium salt for non-glioma type of tumor, and a sodium/potassium salt for treating glioma. The polyunsaturated fatty acid content in the admixture may be in the range of 0.5 mg to 50 gm. The cytokine (lymphokine) may be tumor necrosis factor and/or interferon. The admixture may be administered orally or parenterally or by methods which are selective combinations, eg., intra-arterial, oral and parenteral. Examples given of cancers treated include hepatoma, giant cell tumor of the bone and glioma. The invention by cutting off blood supply to the tumor region causes massive necrosis of the cancerous cells, and prevents angiogenic activity in the tumor region.

IPC 1-7

**A61K 31/20**; **A61K 45/06**; **A61P 35/00**; **A61K 47/44**; **A61K 47/48**

IPC 8 full level

**A61K 47/46** (2006.01); **A61K 31/201** (2006.01); **A61K 31/202** (2006.01); **A61K 31/255** (2006.01); **A61K 31/28** (2006.01); **A61K 31/475** (2006.01); **A61K 31/48** (2006.01); **A61K 31/555** (2006.01); **A61K 31/557** (2006.01); **A61K 31/704** (2006.01); **A61K 33/00** (2006.01); **A61K 38/00** (2006.01); **A61K 38/21** (2006.01); **A61K 45/06** (2006.01); **A61K 47/48** (2006.01); **A61K 49/04** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)

**A61K 31/201** (2013.01); **A61K 31/202** (2013.01); **A61K 31/28** (2013.01); **A61K 31/557** (2013.01); **A61K 33/00** (2013.01); **A61K 45/06** (2013.01); **A61K 49/0461** (2013.01); **A61P 35/00** (2017.12)

C-Set (source: EP)

1. **A61K 31/201** + **A61K 2300/00**
2. **A61K 31/202** + **A61K 2300/00**
3. **A61K 31/28** + **A61K 2300/00**
4. **A61K 33/00** + **A61K 2300/00**

Citation (search report)

See references of WO 0117524A1

Designated contracting state (EPC)

DE ES FR GB IT

DOCDB simple family (publication)

**WO 0117524 A1 20010315**; AU 5928599 A 20010410; EP 1214067 A1 20020619; JP 2003508487 A 20030304

DOCDB simple family (application)

**US 9921711 W 19990920**; AU 5928599 A 19990920; EP 99946993 A 19990920; JP 2001521315 A 19990920